Bioventus Inc.

Total Valuation

Bioventus Inc. carries a market capitalization of 787.91M, placing it among publicly traded companies globally. Its enterprise value stands at 892.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bioventus Inc. currently has 67.64M shares outstanding.

Valuation Ratios

Bioventus Inc. trades at a trailing price-to-earnings ratio of 21.46. The price-to-sales ratio is 1.06, and the price-to-book ratio stands at -1.84.

Enterprise Valuation

On an enterprise value basis, Bioventus Inc. trades at an EV/EBITDA multiple of 8.38 and an EV/FCF ratio of 6.91. The EV/Sales ratio of 1.55 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.83 provides insight into valuation relative to core operating earnings.

Financial Position

Bioventus Inc. maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.14, indicating elevated leverage, while an interest coverage ratio of 4.57 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Bioventus Inc. has paid -899,000.00 in income taxes, reflecting an effective tax rate of 36.95.

Stock Price Statistics

Bioventus Inc.'s stock has gained approximately 79.7527% over the past 52 weeks. The 50-day moving average sits at 10.02, while the 200-day moving average is 8.63.

Income Statement

Over the trailing twelve months, Bioventus Inc. generated 576.30M in revenue and converted that into 28.48M in net income, yielding earnings per share of 0.50. EBITDA reached 106.56M, while operating income came in at 60.21M.

Balance Sheet

Bioventus Inc. holds 35.85M in cash and equivalents against 272.08M in total debt, resulting in a net debt position of 236.23M. Total book value stands at -331.73M, with working capital of 101.72M providing operational flexibility.

Cash Flow

Bioventus Inc. produced 102.94M in operating cash flow over the past twelve months. After subtracting -2.31M in capital expenditures, free cash flow totaled 100.63M - equivalent to 1.50 per share.

Margins

Bioventus Inc. operates with a gross margin of 68.69, reflecting its pricing power and cost economics. The operating margin of 10.45 and net profit margin of 4.94 provide insight into operational efficiency.

Dividends & Yields

Scores

Bioventus Inc. posts an Altman Z-Score of 2.41, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.